INR731 for Prostate Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this study is to assess the safety, tolerability, pharmacokinetics/pharmacodynamics, preliminary anti-tumor activity, and recommended dose of INR731 as a single agent and in combination with standard-of-care androgen receptor pathway inhibitors (ARPIs) in adult patients with metastatic prostate cancer.
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment - Dose Escalation
Participants receive INR731 as a single agent or in combination with enzalutamide or abiraterone to determine the recommended dose
Treatment - Dose Expansion
Further exploration of safety, tolerability, and preliminary anti-tumor activity at the recommended dose
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Abiraterone
- Enzalutamide
- INR731
How Is the Trial Designed?
3
Treatment groups
Experimental Treatment
The dose escalation part with single agent INR731 may be followed by a dose expansion part.
The dose escalation part with INR731 in combination with enzalutamide may be followed by a dose expansion part.
Dose escalation of INR731 in combination with abiraterone.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Novartis Pharmaceuticals
Lead Sponsor
Dr. Vas Narasimhan
Novartis Pharmaceuticals
Chief Executive Officer since 2018
MD from Harvard Medical School
Dr. Shreeram Aradhye
Novartis Pharmaceuticals
Chief Medical Officer since 2021
MD
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.